About Us
About Us
Advancing innovative antibody therapeutics for patients
Advancing innovative antibody therapeutics for patients
Founded in 2015, Qilu Puget Sound Biotherapeutic Corp. (d.b.a. Sound Biologics) is a privately held clinical-stage biotechnology company in the greater Seattle area developing innovative monoclonal antibody therapeutics.
Founded in 2015, Qilu Puget Sound Biotherapeutic Corp. (d.b.a. Sound Biologics) is a privately held clinical-stage biotechnology company in the greater Seattle area developing innovative monoclonal antibody therapeutics.
Founded in 2015, Qilu Puget Sound Biotherapeutic Corp. (d.b.a. Sound Biologics) is a privately held clinical-stage biotechnology company in the greater Seattle area developing innovative monoclonal antibody therapeutics.
Contact Us ➤
Contact Us ➤
Our experienced team brings expertise in antibody discovery and engineering, preclinical research, and early-stage biopharmaceutical development, including protein characterization and formulation. Working with our collaborators, we have advanced antibody therapeutics from discovery through clinical development, including a MabPair product that has reached commercialization.
Our experienced team brings expertise in antibody discovery and engineering, preclinical research, and early-stage biopharmaceutical development, including protein characterization and formulation. Working with our collaborators, we have advanced antibody therapeutics from discovery through clinical development, including a MabPair product that has reached commercialization.
Our proprietary technology platforms enable the development of two or more completely different antibody therapeutics to address complex disease biology. MabPair combines two distinct monoclonal antibodies within one drug entity, while our bispecific platform provides a complementary approach to multi-target intervention through a single molecule. MabPair products could offer many advantages over the conventional combination of two individual antibodies.
Our proprietary technology platforms enable the development of two or more completely different antibody therapeutics to address complex disease biology. MabPair combines two distinct monoclonal antibodies within one drug entity, while our bispecific platform provides a complementary approach to multi-target intervention through a single molecule. MabPair products could offer many advantages over the conventional combination of two individual antibodies.
Leadership Team
Our leadership team brings extensive experience across antibody research, development, and biopharmaceutical sciences, with experience advancing innovative biologic therapeutics from early discovery toward clinical development and beyond.
Meet Our Leadership ➤
Leadership Team
Our leadership team brings extensive experience across antibody research, development, and biopharmaceutical sciences, with experience advancing innovative biologic therapeutics from early discovery toward clinical development and beyond.
Meet Our Leadership ➤
